中华乳腺病杂志（电子版）
中華乳腺病雜誌（電子版）
중화유선병잡지（전자판）
CHINESE JOURNAL OF BREAST DISEASE(ELECTRONIC VERSION)
2009年
4期
424-428
,共5页
乳腺肿瘤%SMYD3%免疫组织化学
乳腺腫瘤%SMYD3%免疫組織化學
유선종류%SMYD3%면역조직화학
Breast neoplasms%SMYD3%Immunohistochemistry
目的 探讨组蛋白甲基转移酶SMYD3在乳腺癌的表达情况及其意义.方法 运用Western blot法检测SMYD3在乳腺癌细胞系的表达,并用免疫组织化学S-P法检测SMYD3在67例乳腺癌组织及10例正常乳腺组织中的表达,最后对SMYD3表达与乳腺癌各临床病理指标行Mann-Whitney U或Kruskal-Wallis H检验分析.结果 SMYD3在MCF-7、MDA-MB-231、SKBR3和 MDA-MB-435s等乳腺癌细胞株中均呈阳性表达,而在正常乳腺组织中均无阳性表达.正常组织与癌性组织之间SMYD3阳性表达的差异有统计学意义(U＝130.00,P=0.001).在乳腺癌组织中,SMYD3的总体阳性率为 61.19%.SMYD3阳性表达在年龄,组织病理级别,病理类型,ER、PR、BCL-2、P53表达等亚组间差异均无统计学意义(P值均>0.050),而在淋巴结转移、HER-2表达亚组间差异有统计学意义(P值均＜0.001).结论 SMYD3阳性表达可作为判断乳腺癌预后的潜在标记物,并有望成为乳腺癌靶向治疗的新靶点.
目的 探討組蛋白甲基轉移酶SMYD3在乳腺癌的錶達情況及其意義.方法 運用Western blot法檢測SMYD3在乳腺癌細胞繫的錶達,併用免疫組織化學S-P法檢測SMYD3在67例乳腺癌組織及10例正常乳腺組織中的錶達,最後對SMYD3錶達與乳腺癌各臨床病理指標行Mann-Whitney U或Kruskal-Wallis H檢驗分析.結果 SMYD3在MCF-7、MDA-MB-231、SKBR3和 MDA-MB-435s等乳腺癌細胞株中均呈暘性錶達,而在正常乳腺組織中均無暘性錶達.正常組織與癌性組織之間SMYD3暘性錶達的差異有統計學意義(U＝130.00,P=0.001).在乳腺癌組織中,SMYD3的總體暘性率為 61.19%.SMYD3暘性錶達在年齡,組織病理級彆,病理類型,ER、PR、BCL-2、P53錶達等亞組間差異均無統計學意義(P值均>0.050),而在淋巴結轉移、HER-2錶達亞組間差異有統計學意義(P值均＜0.001).結論 SMYD3暘性錶達可作為判斷乳腺癌預後的潛在標記物,併有望成為乳腺癌靶嚮治療的新靶點.
목적 탐토조단백갑기전이매SMYD3재유선암적표체정황급기의의.방법 운용Western blot법검측SMYD3재유선암세포계적표체,병용면역조직화학S-P법검측SMYD3재67례유선암조직급10례정상유선조직중적표체,최후대SMYD3표체여유선암각림상병리지표행Mann-Whitney U혹Kruskal-Wallis H검험분석.결과 SMYD3재MCF-7、MDA-MB-231、SKBR3화 MDA-MB-435s등유선암세포주중균정양성표체,이재정상유선조직중균무양성표체.정상조직여암성조직지간SMYD3양성표체적차이유통계학의의(U＝130.00,P=0.001).재유선암조직중,SMYD3적총체양성솔위 61.19%.SMYD3양성표체재년령,조직병리급별,병리류형,ER、PR、BCL-2、P53표체등아조간차이균무통계학의의(P치균>0.050),이재림파결전이、HER-2표체아조간차이유통계학의의(P치균＜0.001).결론 SMYD3양성표체가작위판단유선암예후적잠재표기물,병유망성위유선암파향치료적신파점.
Objective To investigate the expression of SET and MYND domain containing protein 3 (SMYD3) in breast cancer and its clinical significance.Methods The expression of SMYD3 in breast cancer cell lines and breast cancer tissues was detected respectively by Western Blot and immunohistochemical SP staining in 67 patients with breast cancer and 10 healthy breasts. The relationship between SMYD3 expression and clinicopathological parameters was analyzed with Mann-Whitney U test or Kruskal-Wallis H test. Results SMYD3 was overexpressed in breast cancer cell lines such as MCF-7, MDA-MB-231, SKBR3 and MDA-MB-435s. Likewise, SMYD3 was found to be overexpressed also in breast cancer tissues, with a positive rate of 61.19% (41/67). No SMYD3 expression was detected in the 10 normal breast tissues 0.00% (0/10). There was a statistical difference in positive expression of SMYD3 between breast cancer tissue and normal breast tissue (U=130.00, P=0.001). There was no statistical difference in positive expression of SMYD3 in age, histopathological grading,
pathological types, ER, PR BCL-2 and P53 expressions between subgroups (all P values >0.05). But the difference of SMYD3 expression in lymph node metastasis and HER-2 expression was statistically significant ( all P values ＜ 0.001).Conclusions SMYD3 can be used as a potential marker in judging breast cancer. SMYD3 may be a promising target in targeted therapy for breast cancer.
